Alnylam Initiates Final Part of Phase I/II Study on ALN-CC5
Alnylam Pharmaceuticals, Inc. ALNY announced that it has initiated the final part of the phase I/II study on ALN-CC5 for the treatment of patients with complement-mediated diseases. The open-label, multi-dose study will evaluate ALN-CC5, administered for up to 13 weeks, on patients with paroxysmal nocturnal hemoglobinuria (PNH). […]